Effect of Recombinant Human Erythropoietin on Quality of Life in Cancer Patients Receiving Chemotherapy: Results of a Randomized, Controlled Trial
- 30 June 2003
- journal article
- clinical trial
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 25 (6) , 512-518
- https://doi.org/10.1016/s0885-3924(03)00070-8
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Anemia and fatigue in cancer patientsCancer, 2001
- The impact of hemoglobin levels on treatment outcomes in patients with cancerSeminars in Oncology, 2001
- The use of epoetin alfa to increase and maintain hemoglobin levels during radiotherapySeminars in Oncology, 2001
- Oxygenation status of malignant tumors: Pathogenesis of hypoxia and significance for tumor therapySeminars in Oncology, 2001
- Symptomatology of anemiaSeminars in Oncology, 2001
- The many causes of quality of life deficits in cancer patientsInternational Journal of Pharmaceutical Medicine, 2000
- Beating fatigue: evaluation of a programme developed to assist patients receiving chemotherapy cope with fatigueEuropean Journal Of Cancer, 1999
- Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancerBritish Journal of Cancer, 1999
- Statistics notes: Multiple significance tests: the Bonferroni methodBMJ, 1995
- Recombinant Human Erythropoietin Therapy for Anemic Cancer Patients on Combination ChemotherapyJNCI Journal of the National Cancer Institute, 1993